Top Markets
Coin of the day
HTG Molecular Diagnostics, Inc. HTG Molecular Diagnostics, Inc.

HTG Molecular Diagnostics, Inc.

HTGM
Rank in Stocks #28757
Based in Tucson, Arizona, HTG Molecular Diagnostics, Inc. is a life sciences... Based in Tucson, Arizona, HTG Molecular Diagnostics, Inc. is a life sciences company dedicated to advancing precision medicine. They provide a comprehensive suite of products, including specialized instruments, assay kit consumables, and software solutions, all designed to automate sample processing and accurately profile various molecular targets. Their extensive portfolio features numerous molecular profiling panels, such as the HTG Transcriptome Panel, HTG EdgeSeq precision immuno-oncology panel, HTG EdgeSeq miRNA whole-transcriptome assay, HTG EdgeSeq DLBCL cell of origin assay (available in both EU and non-EU versions), HTG EdgeSeq Oncology Biomarker Panel, HTG EdgeSeq ALKPlus assay EU, HTG EdgeSeq Pan B-Cell Lymphoma Panel, HTG immune response panel, and HTG mouse mRNA tumor response panel. The company directly distributes its instruments and consumables across the United States and Europe, while utilizing distributors for other international markets and specific European regions. Their diverse clientele includes biopharmaceutical companies, academic research centers, and molecular testing laboratories. Additionally, HTG Molecular Diagnostics, Inc. maintains a governing agreement with QIAGEN Manchester Limited. The company was founded in 1997 as HTG, Inc., and officially changed its name to HTG Molecular Diagnostics, Inc. in March 2011.
Share Price
$0.48
Last synced: 2023-06-14
Market Cap
$24.79M
Change (1 day)
-20.00%
Change (1 year)
0.00%
Country
US
Trade HTG Molecular Diagnostics, Inc. (HTGM)

Category

P/E ratio for HTG Molecular Diagnostics, Inc. (HTGM)
P/E ratio as of 2026 TTM: 0
According to HTG Molecular Diagnostics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for HTG Molecular Diagnostics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
31.59 -
US
35.83 -
US
- -
CN
-227.89 -
US
38.69 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.